| MeSH term | MeSH ID | Detail |
|---|---|---|
| Abnormalities, Drug-Induced | D000014 | 10 associated lipids |
| Abortion, Spontaneous | D000022 | 12 associated lipids |
| Abscess | D000038 | 13 associated lipids |
| Achlorhydria | D000126 | 1 associated lipids |
| Actinomycetales Infections | D000193 | 4 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Angina Pectoris | D000787 | 27 associated lipids |
| Arrhythmias, Cardiac | D001145 | 42 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
| Arthritis | D001168 | 41 associated lipids |
| Arthritis, Infectious | D001170 | 8 associated lipids |
| Bacterial Infections | D001424 | 21 associated lipids |
| Bacteriuria | D001437 | 7 associated lipids |
| Barrett Esophagus | D001471 | 3 associated lipids |
| Bartonella Infections | D001474 | 3 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Boutonneuse Fever | D001907 | 5 associated lipids |
| Bradycardia | D001919 | 13 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Bronchiectasis | D001987 | 7 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (2)
- Clin. Infect. Dis. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (2)
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Gisbert JP et al. | Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy. | 2000 | Aliment. Pharmacol. Ther. | pmid:10971230 |
| Beyer G et al. | Impact of moxifloxacin versus clarithromycin on normal oropharyngeal microflora. | 2000 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:10968328 |
| Heep M et al. | Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. | 2000 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:10968325 |
| Katsura Y et al. | Anti-Helicobacter pylori agents. 4. 2-(Substituted guanidino)-4-phenylthiazoles and some structurally rigid derivatives. | 2000 | J. Med. Chem. | pmid:10966750 |
| Ozkan Y et al. | Clarithromycin targeting to lung: characterization, size distribution and in vivo evaluation of the human serum albumin microspheres. | 2000 | Farmaco | pmid:10966162 |
| Castellote J and Porta F | [Combination of ranitidine and bismuth citrate plus 2 antibiotics in the eradication of Helicobacter pylori]. | 2000 | Med Clin (Barc) | pmid:10965489 |
| Scaglione F et al. | In vitro comparative dynamics of modified-release clarithromycin and of azithromycin. | 2000 Sep-Oct | Chemotherapy | pmid:10965100 |
| McCarty JM | Clarithromycin in the management of community-acquired pneumonia. | 2000 | Clin Ther | pmid:10963284 |
| Dupas JL et al. | [Acid suppression therapy is not required after one-week anti-Helicobacter pylori triple therapy for duodenal ulcer healing]. | 2000 Jun-Jul | Gastroenterol. Clin. Biol. | pmid:10962387 |
| Hatipoglu ON and Tasan Y | A comparative efficacy and safety study of clarithromycin, roxithromycin and erythromycin stearate in mild pneumonia. | 2000 | Yonsei Med. J. | pmid:10957888 |
| Fujiue Y et al. | [Results of antimicrobial susceptibilities of strains clinically isolated at 8 institutions in Hiroshima City to major oral antimicrobial drugs, mainly new quinolone drugs. Hiroshima Levofloxacin Susceptibility Surveillance Group]. | 2000 | Jpn J Antibiot | pmid:10955237 |
| Piqué JM | [Helicobacter pylori eradication in gastroduodenal ulcer: good, fine and not expensive]. | 2000 | Med Clin (Barc) | pmid:10953833 |
| Gomollón F et al. | [Cost-effectiveness analysis of 2 strategies of Helicobacter pylori eradication: results of a prospective and randomized study in primary care]. | 2000 | Med Clin (Barc) | pmid:10953829 |
| Boxenbaum H | Human in vivo competitive inhibition of P450 substrates: increased plasma concentrations as a function of hepatic extraction ratio and percent inhibition. | 1999 Sep-Dec | J Pharm Pharm Sci | pmid:10953254 |
| Mayhew BS et al. | An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. | 2000 | Drug Metab. Dispos. | pmid:10950845 |
| Katz VL et al. | Mycobacterium chelonae sepsis associated with long-term use of an intravenous catheter for treatment of hyperemesis gravidarum. A case report. | 2000 | J Reprod Med | pmid:10948471 |
| Sato K and Ebe T | [A study on the effect of combined chemotherapy on Mycobacterium avium complex pulmonary disease]. | 2000 | Kekkaku | pmid:10944891 |
| Daudén E et al. | Helicobacter pylori and idiopathic chronic urticaria. | 2000 | Int. J. Dermatol. | pmid:10944090 |
| Kamochi H et al. | Clarithromycin associated with torsades de pointes. | 1999 | Jpn. Circ. J. | pmid:10943628 |
| Shivkumar K | Images in cardiovascular medicine. Labile repolarization from "cell to bedside". | 2000 | Circulation | pmid:10942753 |
| Narita N | "Multi-effect" macrolides. | 2000 | Intern. Med. | pmid:10939528 |
| Morlet-Barla N et al. | [Severe hypoglycemia and recurrence caused by disopyramide-clarithromycin interaction]. | 2000 Jul 8-15 | Presse Med | pmid:10938688 |
| Kihara Y and Otsuki M | Interaction of gliclazide and rifampicin. | 2000 | Diabetes Care | pmid:10937528 |
| Theron AJ et al. | Investigation of the anti-inflammatory and membrane-stabilizing potential of spiramycin in vitro. | 2000 | J. Antimicrob. Chemother. | pmid:10933651 |
| Gücüyener K et al. | Methyl-prednisolone in neurologic complications of Mycoplasma pneumonia. | 2000 | Indian J Pediatr | pmid:10932970 |
| Yamashita H et al. | When can complete regression of low-grade gastric lymphoma of mucosa-associated lymphoid tissue be predicted after helicobacter pylori eradication? | 2000 | Histopathology | pmid:10931236 |
| Savarino V et al. | OAM for cure of Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930908 |
| Kamada T et al. | Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of helicobacter pylori in smokers. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930905 |
| Kihira K et al. | Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930904 |
| Pilotto A et al. | Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930903 |
| Lai KC et al. | Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930902 |
| Hurenkamp GJ et al. | Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer disease. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930901 |
| Van Oijen AH et al. | Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930892 |
| Nagaya T et al. | A potential role of activated NF-kappa B in the pathogenesis of euthyroid sick syndrome. | 2000 | J. Clin. Invest. | pmid:10930442 |
| Hammerschlag MR | Treatment of Chlamydia pneumoniae. | 2000 | Int. J. Antimicrob. Agents | pmid:10926449 |
| Pamuk ON et al. | Are Turkish Helicobacter pylori strains gaining resistance against clarithromycin? | 2000 | Am. J. Gastroenterol. | pmid:10926000 |
| Frueh BE et al. | Mycobacterium szulgai keratitis. | 2000 | Arch. Ophthalmol. | pmid:10922211 |
| Lerner FE et al. | Clarithromycin bioequivalence study of two oral formulations in healthy human volunteers. | 2000 | Int J Clin Pharmacol Ther | pmid:10919343 |
| McCarty J et al. | Clarithromycin suspension vs penicillin V suspension in children with streptococcal pharyngitis. | 2000 Jan-Feb | Adv Ther | pmid:10915400 |
| Miwi H et al. | Comparison of the efficacy of 400mg and 800mg of clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection in a Japanese population. | 2000 | J. Gastroenterol. | pmid:10905362 |
| Moayyedi P et al. | Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group. | 2000 | Lancet | pmid:10905240 |
| Bortolotti M et al. | Dose-related stimulatory effect of clarithromycin on interdigestive gastroduodenal motility. | 2000 | Digestion | pmid:10899723 |
| Kato M et al. | Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. | 2000 | Antimicrob. Agents Chemother. | pmid:10898707 |
| Jordan MK et al. | Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics. | 2000 | Antimicrob. Agents Chemother. | pmid:10898693 |
| Jamal MA et al. | Molecular basis of clarithromycin-resistance in Mycobacterium avium intracellulare complex. | 2000 | Tuber. Lung Dis. | pmid:10897378 |
| Konno M et al. | Iron-deficiency anemia associated with Helicobacter pylori gastritis. | 2000 | J. Pediatr. Gastroenterol. Nutr. | pmid:10896071 |
| Toutous-Trellu L et al. | Three cases of cutaneous sarcoidosis: search for bacterial agent by the 16S RNA gene analysis and treatment with antibiotics. | 2000 | Dermatology (Basel) | pmid:10894973 |
| Lamouliatte H et al. | [Treatment of Helicobacter pylori infection with lansoprazole 30 mg or 60 mg combined with two antibiotics for duodenal ulcers]. | 2000 | Gastroenterol. Clin. Biol. | pmid:10891736 |
| Sung JJ et al. | Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. | 2000 | Gastroenterology | pmid:10889149 |
| Wang WH et al. | High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. | 2000 | Aliment. Pharmacol. Ther. | pmid:10886046 |